Drug search by name

Crixivan and Nephrolithiasis

Result of checking the interaction of drug Crixivan and disease Nephrolithiasis for safety when used together.

Check result:

Crixivan <> Nephrolithiasis

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Crystalluria and nephrolithiasis may occur during treatment with indinavir. The cumulative frequency of nephrolithiasis is substantially higher in pediatric patients (29%) than in adult patients (12.4%; range 4.7% to 34.4% across individual trials) and increases with duration of exposure to indinavir; however, the risk over time remains relatively constant. The incidence is also higher when indinavir is used in combination with ritonavir than when used alone at 800 mg three times a day. In some cases, nephrolithiasis/urolithiasis has been associated with renal insufficiency or acute renal failure and pyelonephritis with or without bacteremia. Therapy with indinavir should be administered cautiously in patients with a current or past history of nephrolithiasis. It is crucial that patients receive adequate hydration. Generally, at least 1.5 L (approximately 48 oz) of fluid per day is recommended for adults during indinavir therapy. Those who are dehydrated may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid if necessary. All patients receiving indinavir should be instructed to seek medical attention if they experience potential signs and symptoms of nephrolithiasis/urolithiasis such as flank pain, hematuria, dysuria, anuria, and urinary urgency. A brief interruption (e.g., 1 to 3 days) or discontinuation of therapy may be required.

References:

Guery B, Tubiana R, Martinez F, Jacquiaud C, Bochet M, Katlama C, Deray G "Renal tolerance of indinavir in HIV-positive patients." Nephron 82 (1999): 72
Rich JD, Ramratnam B, Chiang M, Tashima KT "Management of indinavir associated nephrolithiasis." J Urol 158 (1997): 2228
Kohan AD, Armenakas NA, Fracchia JA "Indinavir urolithiasis: An emerging cause of renal colic in patients with human immunodeficiency virus." J Urol 161 (1999): 1765-8
Grunke M, Valerius T, Manger B, Kalden JR, Harrer T "Renal dysfunction in a human immunodeficiency virus-infected patient who was treated with indinavir." Clin Infect Dis 25 (1997): 1270-1
Padberg J, Fritsche L, Bergmann F, Schurmann D, Suttorp N "Nephropathy and renal colic in patients treated with indinavir, ritonavir plus indinavir or ritonavir plus saquinavir." AIDS 13 (1999): 2173-4
Famularo G, Di Toro S, Moretti S, De Simone C "Symptomatic crystalluria associated with indinavir." Ann Pharmacother 34 (2000): 1414-8
Sarcletti M, Petter A, Zangerle R "Indinavir and interstitial nephritis." Ann Intern Med 128 (1998): 320-1
Dieleman JP, Gyssens IC, vanderEnde ME, deMarie S, Burger DM "Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients." AIDS 13 (1999): 473-8
Polhemus ME, Aronson NE "Persistent nephrolithiasis after discontinuation of indinavir therapy." Clin Infect Dis 27 (1998): 1536-7
Sutherland SE, Reigle MD, Seftel AD, Resnick MI "Protease inhibitors and urolithiasis." J Urol 158 (1997): 31-3
Martinez E, Leguizamon M, Mallolas J, Miro JM, Gatell JM "Influence of environmental temperature on incidence of indinavir-related nephrolithiasis." Clin Infect Dis 29 (1999): 422-5
Kopp JB, Miller KD, Mican JA, et al. "Crystalluria and urinary tract abnormalities associated with indinavir." Ann Intern Med 127 (1997): 119-25
Jaradat M, Phillips C, Yum MN, Cushing H, Moe S "Acute tubulointerstitial nephritis attributable to indinavir therapy." Am J Kidney Dis 35 (2000): e161-5
Ascher DP, Lucy MD "Indinavir sulfate renal toxicity in a pediatric hemophiliac with HIV infection." Ann Pharmacother 31 (1997): 1146-9
Brodie SB, Keller MJ, Ewenstein BM, Sax PE "Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients." AIDS 12 (1998): 2433-7
Vigano A, Rombola G, diBelgioioso GB, Sala N, Principi N "Subtle occurrence of indinavir-induced acute renal insufficiency." AIDS 12 (1998): 954-5
Perazella MA, Kashgarian M, Cooney E "Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria." Clin Nephrol 50 (1998): 194-6
Bruce RG, Munch LC, Hoven AD, Jerauld RS, Greenburg R, Porter WH, Rutter PW "Urolithiasis associated with the protease inhibitor indinavir." Urology 50 (1997): 513-8
Gagnon RF, Tsoukas CM, Watters AK "Light microscopy of indinavir urinary crystals." Ann Intern Med 128 (1998): 321
Bach MC, Godofsky EW "Indinavir nephrolithiasis in warm climates." J Acquir Immune Defic Syndr Hum Retrovirol 14 (1997): 296-7
Antony SJ "Rapid development of indinavir-induced asymptomatic crystalluria in a human immunodeficiency virus-negative patient." Clin Infect Dis 27 (1998): 911-2
Berns JS, Cohen RM, Silverman M, Turner J "Acute renal failure due to indinavir crystalluria and nephrolithiasis: report of two cases." Am J Kidney Dis 30 (1997): 558-60
"Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.
Grabe DW, Eisele G, Miller C, Singh J, Stein D "Indinavir-induced nephropathy." Clin Nephrol 51 (1999): 181-3
Daudon M, Estepa L, Viard JP, Joly D, Jungers P "Urinary stones in HIV-1-positive patients treated with indinavir." Lancet 349 (1997): 129-45
Noble CB, Klein LT, Staiman VR, Neu N, Hensle TW, Berdon WE "Ureteral obstruction secondary to indinavir in the pediatric HIV population." Pediatr Radiol 28 (1998): 627-9
Salahuddin S, Hsu YS, Buchholz NP, Dieleman JP, Gyssens IC, Kok DJ "Is indinavir crystalluria an indicator for indinavir stone formation?." Aids 15 (2001): 1079-80
Reiter WJ, SchonPernerstorfer H, Dorfinger K, Hofbauer J, Marberger M "Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed." J Urol 161 (1999): 1082-4
Gentle DL, Stoller ML, Jarrett TW, Ward JF, Geib KS, Wood AF "Protease inhibitor-induced urolithiasis." Urology 50 (1997): 508-11
Lerner LB, Cendron M, Rous SN "Nephrolithiasis from indinavir, a new human immunodeficiency virus drug." J Urol 159 (1998): 2074-5
Boubaker K, Sudre P, Bally F, Vogel G, Meuwly JY, Glauser MP, Telenti A "Changes in renal function associated with indinavir." AIDS 12 (1998): f249-54
Marroni M, Gaburri M, Mecozzi F, Baldelli F "Acute interstitial nephritis secondary to the administration of indinavir." Ann Pharmacother 32 (1998): 843-4
Tashima KT, Horowitz JD, Rosen S "Indinavir nephropathy." N Engl J Med 336 (1997): 138-40
Tsao JW, Kogan SC "Indinavir crystalluria." N Engl J Med 340 (1999): 1329